QNTM
Quantum BioPharma Ltd. (QNTM) Economic Moat Analysis (2026)
Overall Score
Profitability Returns
TTM returns remain deeply negative, with ROA at -1.73%, ROE at -4.13%, and ROIC at -0.27%.
Operating margins are still effectively zero, indicating no durable pricing power or scale advantage in the current period.
Cash Generation
Operating cash flow and free cash flow remain negative on a TTM basis, with FCF yield at -0.27% and OCF yield at -0.65%.
Cash conversion remains weak despite low capex, suggesting the business is not yet translating revenue into sustainable cash generation.
Balance Sheet Resilience
Liquidity is adequate with a current ratio of 1.20 and quick ratio of 1.19.
Leverage remains modest, with debt-to-equity at 0.12 and debt-to-assets at 0.07, providing some cushion despite weak earnings.
Moat Indicators
There is no clear evidence of pricing power or operating leverage, as margins and returns remain near zero or negative.
Inventory turnover of 4.74 and a 77-day operating cycle do not yet indicate a strong efficiency advantage.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Quantum BioPharma Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

